Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Recurrent or Progressive IDH Mutant Gliomas
NCT03557359Phase 2Completed
- Start
- Jun 2018
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in glioma. Started Jun 2018; status: completed.
02
Drugs
03
Conditions
glioma
Beyond the preview
Go deeper on NCT03557359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03557359.